Every hour of every day, in the United States, one American dies of oral cancer. This deadly disease is the sixth leading cause of cancer deaths in America with no significant improvement in the survival rate in the past 40 years.
If discovered in its early stages, oral cancer is 90 percent curable, but less than 50 percent curable if discovered in its later stages. To help increase survivability, Dr. Bishop, offers her patients the benefits of ViziLite, the only FDA-cleared technology for screening of oral abnormalities in patients at increased risk for oral cancer. ViziLite, marketed by Zila Pharmaceuticals, a division of Zila, Inc. (Nasdaq: ZILA), is a medical breakthrough that helps professionals detect oral abnormalities that could be early indicators of cancer.
ViziLite is an easy, painless and non-invasive examination that more and more dentists are incorporating into their annual oral health wellness exam. The exam is a three-step process and takes only a few minutes. First, the patient rinses with a raspberry-tasting solution to prepare for the exam after which the dentist snaps the ViziLite lightstick, activating it so that it glows. The dentist then places the lightstick in a retractor and shines it in the patient’s mouth while examining the oral tissue for abnormalities
